Aegerion appoints Paul Merrigan marketing VP
This article was originally published in Scrip
Executive Summary
Aegerion Pharmaceuticals, a biopharmaceutical company developing novel therapeutics to treat severe lipid disorders, has appointed Paul Merrigan vice-president of global marketing. Mr Merrigan most recently served as vice-president and general manager of neuromuscular diseases at Genzyme, where he had previously held many other positions.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.